Dose Insider / Glossary / Qsymia

QsymiaWhat it is, how the dose is set and what it did in trials

Updated November 20, 2026 路 3 min read 路 QSYMIA prescribing information, DailyMed, April 2026

Qsymia is a once-daily capsule that combines two older medicines, phentermine, an appetite suppressant, and topiramate, a seizure and migraine medicine. Used with a reduced-calorie diet and more physical activity, it is approved to lower body weight and keep it off.

10.9%15 mg/92 mg, weight lost in one year
Weight lost in one yearAdults with obesity, % of starting weight15 mg/92 mg10.9%3.75 mg/23 mg5.1%Placebo1.6%Weight lost in one yearAdults with obesity, % of starting weight15 mg/92 mg10.9%3.75 mg/23 mg5.1%Placebo1.6%

47% on the top dose lost at least 10% of their weight, against 7% on placebo.

On this page

The label covers adults and children aged 12 and older with obesity, and adults with overweight and at least one weight-related condition. It was first approved in the United States in 2012, is a controlled substance in schedule IV, and is not a GLP-1 medicine.1

What it is

The label calls phentermine a sympathomimetic amine anorectic, a stimulant-type drug that reduces appetite. On its own it is used for a limited time to speed weight loss.1,2 Topiramate on its own is used to treat certain seizures and to prevent migraine headaches.3 In Qsymia both are in one extended-release capsule, and the label writes each strength as a pair: phentermine in milligrams first, topiramate second.

How the dose is set

Qsymia is taken once a day in the morning, with or without food; the label advises against evening doses because of insomnia. The schedule has two checks built in.1

The top dose is not stopped all at once: the label asks for a gradual stop to avoid a possible seizure. People with moderate or severe kidney impairment or moderate liver impairment stay at 7.5 mg/46 mg at most.1

What it did in trials

Two one-year trials in adults support the approval.1

For context, Wegovy 2.4 mg lowered weight by 14.9% over 68 weeks in its own trial; the two were never compared directly.4

Side effects and warnings

The most common side effects differ from those of the GLP-1 medicines. On the top dose, tingling of the skin, known as paresthesia, was reported by 20% against 2% on placebo. Dry mouth was reported by 19% against 3%, constipation by 16% against 6% and a change in taste by 9% against 1%.1 Heart rate also rises: a rise of more than 10 beats per minute at some point was seen in 56.1% on the top dose against 42.1% on placebo.1

The most serious warning concerns pregnancy. Topiramate taken in the first trimester raises the risk of major birth defects, including cleft lip and cleft palate. Qsymia must not be taken in pregnancy, and for anyone who can become pregnant the label recommends a negative pregnancy test before starting and monthly during treatment, plus effective contraception. For that reason it is available only through a restricted program, a REMS. It is also ruled out with glaucoma, an overactive thyroid and within 14 days of a monoamine oxidase inhibitor.1

Qsymia in eight lines

FactQsymia
Active ingredientsPhentermine and topiramate
First U.S. approval2012
FormExtended-release capsule, once a day
Usual dose7.5 mg/46 mg
Top dose15 mg/92 mg
Controlled substanceSchedule IV
PregnancyRuled out; monthly tests advised
Youngest age12

QSYMIA prescribing information, DailyMed version of April 24, 2026.1

Contrave is the other combination tablet for weight, built from naltrexone and bupropion. Birth control also comes up with the GLP-1 medicines, for a different reason: our page on Zepbound and birth control explains why the pill may work less well after a dose increase.

Sources

  1. QSYMIA (phentermine and topiramate extended-release capsules) prescribing information. Vivus LLC; DailyMed, U.S. National Library of Medicine, version published April 24, 2026; sections 1, 2, 4, 5, 6.1, 8.1 and 14. dailymed.nlm.nih.gov
  2. MedlinePlus. Phentermine. U.S. National Library of Medicine; last revised December 15, 2024, read November 20, 2026. medlineplus.gov
  3. MedlinePlus. Topiramate. U.S. National Library of Medicine; last revised May 15, 2026, read November 20, 2026. medlineplus.gov
  4. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov

Related analyses

Log each capsule and your weight, and see the 12-week checks coming.

Open Dose Insider